Incyte | INCY - Market Capitalization


Incyte reported $27.06B in Market Capitalization this September of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.33B 537M Jun/2026
Agenus USD 128M 21M Mar/2026
Alnylam Pharmaceuticals USD 40.19B 3.96B Jun/2026
Amgen USD 195.44B 5.55B Jun/2026
BioCryst Pharmaceuticals USD 2.54B 880M Jun/2026
Biogen USD 31.9B 5B Jun/2026
BioMarin Pharmaceutical USD 11.06B 196M Jun/2026
Bristol-Myers Squibb USD 117.66B 6.17B Jun/2026
Eli Lilly USD 1.13T 260.54B Jun/2026
Exelixis USD 13.54B 2.65B Jun/2026
Gilead Sciences USD 156.86B 16.13B Jun/2026
Incyte USD 22.65B 3.92B Jun/2026
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
MacroGenics USD 184M 82M Mar/2026
Merck USD 317.37B 20.27B Jun/2026
Nektar Therapeutics USD 2.12B 1.26B Mar/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Novartis USD 240.59B 67.17B Jun/2026
Novartis USD 288.26B 25.18B Mar/2026
Pfizer USD 138.44B 15.37B Jun/2026
Regeneron Pharmaceuticals USD 65.37B 16.31B Jun/2026
Sarepta Therapeutics USD 1.9B 388M Jun/2026
Ultragenyx Pharmaceutical USD 3.29B 1.23B Jun/2026
Vertex Pharmaceuticals USD 126.07B 12.49B Jun/2026